A Registry for People With T-cell Lymphoma

Inclusion criteria

• Written informed consent
• Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
• Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of the following diagnostic criterion (based on WHO classification and NCCN guidelines):

• T-cell prolymphocytic leukemia
• T-cell large granular lymphocytic leukemia
• Chronic lymphoproliferative disorder of NK cells
• Aggressive NK-cell leukemia
• Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
• Chronic active EBV infection of T- and NK-cell type, systemic form
• Hydroa vacciniforme-like lymphoproliferative disorder
• Adult T-cell leukemia/lymphoma
• Extranodal NK/T-cell lymphoma, nasal type
• Enteropathy-associated T-cell lymphoma
• Monomorphic epitheliotropic intestinal T-cell lymphoma
• Intestinal T-cell lymphoma, not otherwise specified (NOS)
• Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
• Hepatosplenic T-cell lymphoma
• Subcutaneous panniculitis-like T-cell lymphoma
• Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
• Sézary syndrome
• Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
• Primary cutaneous Gamma-Delta T-cell lymphoma
• Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
• Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
• Peripheral T-cell lymphoma, not otherwise specified
• Angioimmunoblastic T-cell lymphoma
• Follicular T-cell lymphoma
• Nodal peripheral T-cell lymphoma with TFH phenotype
• Anaplastic large cell lymphoma, ALK-positive
• Anaplastic large cell lymphoma, ALK-negative
• Breast-implant associated anaplastic large cell lymphoma.
• NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.

Exclusion criteria

• Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
• Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.